Utilization of Genetic Counseling after Direct‐to‐Consumer Genetic Testing: Findings from the Impact of Personal Genomics (PGen) Study by Koeller, Diane R et al.
ORIGINAL RESEARCH
Utilization of Genetic Counseling after Direct-to-Consumer
Genetic Testing: Findings from the Impact of Personal Genomics
(PGen) Study
Diane R Koeller1,2 & Wendy R Uhlmann3 & Deanna Alexis Carere4 & Robert C Green3 &
J Scott Roberts2,5 & for the PGen Study Group
Received: 14 February 2017 /Accepted: 25 April 2017 /Published online: 16 May 2017
# National Society of Genetic Counselors, Inc. 2017
Abstract Direct-to-consumer personal genomic testing
(DTC-PGT) results lead some individuals to seek genetic
counseling (GC), but little is known about these consumers
and why they seek GC services. We analyzed survey data pre-
and post-PGT from 1026 23andMe and Pathway Genomics
customers. Participants were mostly white (91%), female
(60%), and of high socioeconomic status (80% college edu-
cated, 43% household income of ≥$100,000). After receiving
PGT results, 43 participants (4%)made or planned to schedule
an appointment with a genetic counselor; 390 (38%) would
have used in-person GC had it been available. Compared to
non-seekers, GC seekers were younger (mean age of 38 vs
46 years), more frequently had children <18 (26% vs 16%),
and were more likely to report previous GC (37% vs 7%) and
genetic testing (30% vs 15%). In logistic regression analysis,
seeking GC was associated with previous GC use (OR = 6.5,
CI = 3.1–13.8), feeling motivated to pursue DTC-PGT for
health reasons (OR = 4.3, CI = 1.8–10.1), fair or poor self-
reported health (OR = 3.1, CI = 1.1–8.3), and self-reported
uncertainty about the results (OR = 1.8, CI = 1.1–2.7). These
findings can help GC providers anticipate who might seek GC
services and plan for clinical discussions of DTC-PGT results.
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Introduction
Direct-to-consumer personal genomic testing (DTC-PGT)
gives people commercial access to personalized genomic in-
formation that ranges from ancestry and physical traits to car-
rier status, medication response, and disease risk. With the
DTC approach, testing is initiated by the individual and gen-
erally does not require involvement of a healthcare provider.
Many tests offered DTC are not considered standard of care
and most are not offered in genetics clinics (Caulfield and
McGuire 2012; Hock et al. 2011; Uhlmann and Sharp
2012). Its limited clinical validity and utility and the lack of
involvement of medical intermediaries have made DTC-PGT
the subject of controversy since its inception (Gutierrez 2013;
Mathews et al. 2012; Wade and Wilfond 2006).
Proponents of DTC-PGTargue that individuals have a right
to direct access to their personal genomic information.
However, others are concerned that obtaining such informa-
tion without a qualified medical intermediary to assist with
pre-test counseling, informed consent, and report interpreta-
tion could be harmful, with the potential for misinterpretation
of test results and distress from unexpected findings
(Gutierrez 2013; Roberts and Ostergren 2013). The clinical
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validity and utility of SNP-based risk profiling for common
diseases offered through DTC services is not well established
at this time. Most of the SNPs analyzed have a very small
effect size and DTC-GT companies are sometimes not consis-
tent in the SNPs they report, resulting in differing risk esti-
mates (Bunnik et al. 2015; Kalf et al. 2014). Of note, evidence
of harm caused by DTC-PGT is limited (Dohany et al. 2012)
and several studies have found no difference between baseline
and follow-up anxiety symptoms amongDTC-PGTcustomers
(Bloss et al. 2011; Bloss et al. 2013; Darst et al. 2013; Francke
et al. 2013; James et al. 2011).
Some of these concerns led the Food and Drug
Administration (FDA) in 2013 to send a warning letter to
the DTC-PGT company 23andMe, ordering them to imme-
diately stop marketing until they obtained official authoriza-
tion (Gutierrez 2013). At that time, 23andMe removed the
health-related testing from products sold to US customers,
but continued to offer ancestry and trait testing. Then in
2015, the FDA approved 23andMe’s marketing of a carrier
test for Bloom syndrome after the company had provided
study data indicating that the test had sufficient accuracy in
detecting carrier status and that consumers could understand
test instructions and results when provided in a DTC format
(Gutierrez 2013). Further, the FDA indicated that related
carrier screening tests for autosomal recessive disorders
would be exempt from their premarket review process,
opening the door for 23andMe and other companies to mar-
ket this particular type of genetic test in a DTC format. In
April 2017, the FDA allowed 23andMe to market tests for
10 additional diseases or conditions, including Parkinson’s
disease, late onset Alzheimer’s disease, and Celiac disease
(FDA 2017).
The above concerns about DTC-PGT prompted genetics
professional societies, including the American College of
Medical Genetics and Genomics (ACMG), the American
Society of Human Genetics (ASHG), and the National
Society of Genetic Counselors to issue position statements.
These statements all advocate for the involvement of genetics
professionals in the testing process (ACMG Board of
Directors 2015; Hudson et al. 2007; NSGC Executive Office
2015). NSGC supports the right of individuals to pursueDTC-
PGT provided the choice is autonomous and informed, but
maintains that companies offering DTC-PGT have a duty to
make genetics professionals easily accessible to customers
(NSGC Executive Office 2015). ACMG advocates that a ge-
netics expert should be available to all DTC-PGT consumers
and should be actively involved in the interpretation and dis-
closure of results (ACMG Board of Directors 2015). ASHG
recommends that companies offering DTC-PGT be transpar-
ent about the risks and limitations of testing; that profession-
al organizations educate providers about this form of testing;
and that federal government agencies regulate DTC-PGT
(Hudson et al. 2007).
While these professional organizations advocate for genet-
ics experts to meet with DTC-PGTcustomers, a survey of 312
genetic counselors found that the field lacks consensus regard-
ing the role that genetic counselors should play (Hock et al.
2011). In this 2008 study, 55% thought genetic counselors
have a professional obligation to be knowledgeable about
DTC-PGT, and 48% felt that genetic counselors should be
able to interpret results. The study also revealed that most
genetic counselors had limited experience working with
DTC-PGT consumers, with only 14% reporting ever having
received requests for test interpretation or discussion (Hock
et al. 2011). Despite the limited involvement of genetic coun-
selors in DTC-PGT to date, Harris et al. (2013) highlighted
several emerging roles for genetic counselors within this field,
including: genetic educator for both consumers and physi-
cians; mediator between consumers and physicians; lifestyle/
health advisor to explain what behavior changes are indicated
by results; risk interpreter; and even entrepreneur (Harris et al.
2013). NSGC does not currently have practice guidelines to
help guide genetic counselors in their interactions with clients
seeking genetic counseling for PGT.
While DTC-PGT does not require genetic counseling at
any point in the testing process, some consumers seek
follow-up with a healthcare provider after receiving their
DTC-PGT results. Previous surveys of consumers of personal
genomic testing (PGT) companies found that 20–40% of par-
ticipants discussed their results with their primary care provid-
er (PCP) and 1–14% discussed them with a genetic counselor
(Bloss et al. 2013; Kaufman et al. 2012; van der Wouden et al.
2016). Although previous studies have examined what leads
DTC-PGT consumers to follow-up with their primary care
provider (PCP) after receiving their results (van der Wouden
et al. 2016;Wasson et al. 2014), we are unaware of any studies
assessing predictors of seeking genetic counseling services
following DTC-PGT. This study aimed to identify such pre-
dictors, thereby enhancing understanding of this patient pop-
ulation and informing counselors’ preparation for clinical
encounters.
Methods
Participants and Procedures
The Impact of Personal Genomics (PGen) Study was a longi-
tudinal survey-based study of new customers from DTC-PGT
service providers 23andMe and Pathway Genomics. During
the time period the study was conducted, 23andMe provided
disease risk information in their results and Pathway
Genomics operated under a DTC model. The study was con-
ducted by a multidisciplinary research team based at Harvard
Medical School / Brigham and Women’s Hospital and the
University of Michigan School of Public Health and aided
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by a team of consultants representing academic and industry
perspectives (Lehmann et al. 2012). Participants were recruit-
ed after placing an order for DTC-PGT through one of the
above companies between March and July 2012.
Participants who purchased DTC-PGT through 23andMe
(the standard cost of which was USD $99) during this time
frame were sent an email from the company describing the
study and inviting them to participate. Members of
PatientsLikeMe, a health-based social networking site, re-
ceived emails offering DTC-PGT through Pathway
Genomics at a subsidized cost of $25 if they participated in
the study. Participants were also recruited through a banner
advertisement on the Pathway Genomics website.
Three web-based surveys were sent by email to participants
through a third-party survey research firm at the following
time-points: 1) baseline after testing was ordered, but before
results were received; 2) approximately 2 weeks after the
DTC-PGT results were viewed; and 3) approximately
6months after the results were viewed. Participants were com-
pensated with electronic gift cards ($10 for completion of the
baseline survey, $20 for the 2 week survey, and $20 for the
6 month survey). Complete details of the study design have
been reported previously (Carere et al. 2014).
The baseline survey was completed by 1464 participants,
1046 of whomwent on to submit the 6 month survey. Of these
participants, 1026 indicated at 6 months whether or not they
had sought GC after receiving their results, and were therefore
eligible to be included in the present analysis.
Measures
Demographics
Demographic information including age, sex, race/ethnicity,
education level, employment status, marital status, and house-
hold income were collected through self-report at baseline.
Personal and Family Health Information
Personal and family medical history was ascertained at base-
line by providing a list of 14 disease categories (e.g., cancer,
diabetes, heart conditions) and asking participants to indicate
if a doctor had ever told them they had the medical condition
(Yes/No). Self-reported health was assessed at baseline using
one item from the SF-36 Short-FormHealth Survey (Ware and
Sherbourne 1992).
Previous Genetics Experience
Previous genetics experience was assessed at baseline by ask-
ing participants whether they had ever met with a genetic
counselor, had genetic testing (and if yes, what type), or pur-
chased PGT through a different company. Diagnostic, carrier,
predictive/presymptomatic, prenatal, and medication response
genetic testing responses were categorized as Bhealth-related,^
while ancestry, trait, and nutrigenomic testing responses were
categorized as Brecreational/lifestyle.^
Motivations and Interests
Motivations for testing were assessed at baseline by asking
participants to rate the importance of 12 listed reasons for
seeking DTC-PGT on a 3-point Likert scale (1 = not at all
important; 2 = somewhat important; 3 = very important). We
created a composite Bhealth-related motivation score^ (possi-
ble range: 5–15) by summing scores from the five scale items
pertinent to the individual’s health or health care planning: 1)
interest in finding out about personal risk for specific diseases,
2) desire to improve health, 3) interest in finding out about
drug response, 4) desire to create a better plan for the future,
and 5) interest in obtaining information about risk of health
conditions for current and future children (Cronbach’s
alpha = 0.77).
Using a 3-point Likert scale (1 = not at all interested;
2 = somewhat interested; 3 = very interested), participants
were asked at baseline to indicate their level of interest in
learning five types of genetic information: risk of disease or
health condition; drug response; carrier status; ancestry; and
traits.
Disease Risk Perceptions
Disease risk perceptions were assessed in the baseline survey.
Participants were given a list of 24 conditions and asked to
compare their chances of developing the disease to the aver-
age man or woman of their age, using a 5-point Likert scale
(1 = much lower than average to 5 = much higher than
average).
Genetic Knowledge
Genetic knowledge was assessed at baseline with nine
true/false statements about genetics and health. These
questions were selected from several validated measures
of assessing genetic knowledge in the lay public
(Bowling et al. 2008; Furr and Kelly 1999; Molster
et al. 2009; Smerecnik et al. 2011). Participants were giv-
en a score of 0–9 based on the sum of their correct
responses (Ostergren et al. 2015).
Numeracy
Numeracy was assessed at baseline with an abbreviated (5
question) version of a validated objective numeracy scale
(Lipkus et al. 2001). Each participant was given a score from
0 to 100 based on their percentage of correct responses.
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Genetic Self-Efficacy
Genetic self-efficacy, or confidence in one’s ability to in-
terpret genetic information, was assessed at baseline with
an adapted version of a published self-efficacy measure
(Ashida et al. 2012; Carere et al. 2016). Participants used
a 7-point Likert scale (1 = strongly disagree to 7 = strongly
agree) to rate their level of agreement or disagreement
with five statements about their confidence in their ability
to understand and use genetic information. Each partici-
pant was given a score of 5–35 based on the sum of their
responses, with higher scores indicating higher genetic
self-efficacy (Cronbach’s alpha = 0.93).
Reactions to Results
Reactions to results were assessed at 2 weeks post-
viewing of results. Participants responded to 13 state-
ments about potential reactions to test results and indicat-
ed how often they experienced these reactions by using a
4-point Likert scale (0 = Never to 3 = Often). This mea-
sure was adapted from a validated measure of psycholog-
ical impact of genetic susceptibility testing (Chung et al.
2009). We created a composite Bresults uncertainty score^
(0–3) by averaging responses to the five scale items
addressing the potential uncertainty of test results
(Cronbach’s alpha = 0.76).
Perceived Utility of Results
Perceived utility of results was assessed on the 6-month sur-
vey using 8 items. Participants were asked to what extent they
agreed or disagreed with statements about the utility of PGT
(i.e. BWhat I learned about my personal genomic testing can
help reduce my chances of getting sick^) on a 5-point Likert
scale (1 = strongly disagree to 5 = strongly agree). Responses
were summed and participants were given a score ranging
from 8 to 40 (Cronbach’s alpha = 0.77).
Use of Medical Services
Use of medical services was assessed on the 6-month
survey by asking which medical professionals (e.g., ge-
netics specialist, primary care provider) the participants
had subsequently scheduled an appointment with to dis-
cuss their DTC-PGT results. Those who indicated they
had met with a PCP and/or with a genetic counselor were
asked to rate their satisfaction with each of these discus-
sions on a 3-point Likert scale (1 = not at all satisfied to
3 = very satisfied). Participants were also asked if they
would have utilized in-person genetic counseling services
had they been available (1 = strongly disagree to
5 = strongly agree).
Data Analysis
Descriptive statistics were used to characterize participants
based on demographics, genetic literacy, genetics self-effica-
cy, numeracy, personal and family medical history, previous
genetics experience, motivations for testing, disease risk per-
ceptions, reactions to results, use of medical services, and
perceived utility of testing.
Participants were divided into 2 groups: GC seekers and
GC non-seekers. GC seekers were those who indicated on the
6-month survey that they had either met or scheduled an ap-
pointment with a genetic counselor to discuss their results.
Those who had neither met with nor made an appointment
with a GC were included in the GC non-seekers group. Chi-
square analyses and t-tests were used to compare the two
groups based on the variables noted above.
Logistic regression was performed to identify predictors of
GC seeking. Regression analysis was performed in a step-wise
fashion. First, a series of univariate regressions was performed
using variables that were found to be most strongly correlated
(those with the lowest p-values) with GC seeking based on chi-
square and t-tests. Then, the variables that were most strongly
associated with GC seeking individually (e.g., those that were
significant at a p-value of <0.05 and had the largest OR) were
fitted into a multivariate regression model in a stepwise fashion.
All data were analyzed using SPSS statistical software.
Statistical significance for analyses was set at p < 0.05.
Results
Out of the total analytic sample of 1026, there were 43 GC
seekers (4%) and 983 GC non-seekers (96%). GC seekers
included both those who had already discussed their results
with a genetics specialist (genetic counselors and geneticists)
(n = 31), and those who had an appointment with a genetics
specialist pending (n = 12). Demographic information, strati-
fied by GC seeking behavior, is presented in Table 1. The
sample was predominantly white (91%), female (60%), mar-
ried (52%), college educated (80%), and wealthy, with 43%
earning a household income of $100,000 or more. The GC
seekers were significantly younger than the non-seekers, with
an average age of 38.1 years (vs 46.2, p < 0.01). GC seekers
were also more likely to have children under the age of
18 years (26 vs 16%, p < 0.01), to be students (16 vs 8%,
p < 0.05), and to be unemployed (19 vs 6%, p < 0.01). GC
seekers and non-seekers were otherwise similar in terms of
sex, race, marital status, income, and education.
Overall, participants had high numeracy, genetics
knowledge, and genetics self-efficacy. GC seekers scored
lower on the objective numeracy test than the non-
seekers, with an average of 4.49 items correct out of 5
(vs 4.71in non-seekers, p < 0.05). GC seekers and non-
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seekers did not significantly differ in their baseline objec-
tive genetic knowledge score (overall sample mean = 8.15,
range 0–9) or genetic self-efficacy score (overall sample
mean = 29.02, range 5–35).
Personal and family health history of the participants is
summarized in Table 2. GC seekers did not report a great-
er number of conditions in their personal medical history,
but they were significantly more likely to report their
genera l heal th as poor or fair (32.6 vs 14.4%,
p < 0.001). GC seekers also reported a higher number of
medical conditions in their family history (7.6 vs 6.6,
p < 0.05) and feeling at risk for a higher number of con-
ditions (4.3 vs 3.0, p < 0.05). GC seekers were more
likely to have had previous genetic counseling (37.2 vs
7.4%, p < 0.001), and previous genetic testing (30.0 vs
14.9%, p < 0.01). The type of previous genetic testing
also differed between the groups, with GC seekers more
frequently having had testing typically offered through
medical professionals (25.6 vs 11.2%, p < 0.05) and less
frequently having previously had recreational testing (2.3
vs 7.2%, p < 0.05).
The motivations for testing are summarized in Table 3. GC
seekers scored higher than non-seekers on our composite
health-related motivations scale (14.3 vs 11.6, p < 0.001).
Compared to non-seekers, GC seekers tended to be more mo-
tivated to pursue PGT due to the following specific factors:
interest in learning about risks to current or future children;
desire to create a better plan for the future; desire to improve
health; and interest in finding out about drug response. When
asked how interested they were in learning about different
types of results, GC seekers were significantly more likely to
report being very interested in carrier status (58.1 vs 31.5%,
p < 0.01) and drug response (74.4 vs 52.8%, p < 0.05) com-
pared to non-seekers.
Reactions to results from the 2-week survey are summa-
rized in Table 4. GC seekers scored higher on our results
reaction uncertainty scale than non-seekers (1.2 vs 0.8,
p < 0.001) and were more likely to endorse the following
specific items: feeling concerned about how their results will
affect insurance status; feeling uncertain about what results
mean about personal risk; feeling unsure of what to do to
prevent disease; having had difficulty talking about results
with others; and feeling motivated to change lifestyle based
on results. At 6 months, GC seekers also rated the perceived
utility of test results as higher than non-seekers (4.2 vs. 3.8,
p < .05). Changes in risk perceptions across time points were
not found to differ significantly between GC seekers and non-
seekers.
While only 3% reported sharing their results with a genetic
counselor (as compared to the 8% who said they intended to
do so in the baseline survey), 29% had shared them with their
PCP and 17% had shared with another medical professional
(e.g., physician assistant, nurse, obstetrician/gynecologist, on-
cologist). Over half (55%) of GC seekers had also shared their
results with their PCP, vs 27% of GC non-seekers. Satisfaction
with discussion of DTC-PGT did not differ significantly by
type of provider, with 13% (vs 18%) feeling not at all satisfied
and 39% (vs 35%) feeling very satisfied with their discussion
with their genetic counselor (vs PCP). 39% of participants
either somewhat (23%) or strongly agreed (16%) that they
would have utilized in-person genetic counseling services
had they been available.
Table 5 summarizes the logistic regression model of vari-
ables associated with GC seeking. Previous GC, being moti-
vated to pursue DTC-PGT for health reasons, reporting poor
general health, and feeling uncertainty about results were most
strongly associated with seeking GC following DTC-PGT.
These variables predict 20.4% of the variance seen in GC
seeking in this study population.
Table 1 Demographics
Variable GC Seekers
(n = 43)
GC Non-seekers
(n = 983)
Mean age in years (sd)**
range
38.1 (11.5)
23–65
46.2 (15.6)
18–93
Sex (% Female) 65.1 59.7
Race (% White) 93.0 90.9
Employment status n (%) n (%)
Full-time 19 (44.2) 513(52.2)
Part-time 4 (9.3) 94 (9.6)
Self-employed 4 (9.3) 87 (8.9)
Retired* 4 (9.3) 206 (21.0)
Student* 7 (16.3) 757 (7.7)
Unemployed** 8 (18.6) 56 (5.7)
Not working by choice 3 (7.0) 53 (5.4)
Incomea n (%) n (%)
< $40,000 14 (32.6) 163 (16.6)
$40,000-69,999 7 (16.3) 182 (18.5)
$70,000–99,999 7 (16.3) 202 (20.6)
$100,000–199,999 9 (20.9) 309 (31.4)
> $200,000 6 (14) 127 (12.9)
Education n (%) n (%)
High school diploma or less 4 (9.3) 36 (3.7)
Some college 13 (30.2) 156 (15.9)
College degree 10 (23.2) 302 (30.7)
Some graduate school 7 (16.3) 112 (11.4)
Master’s degree or higher 9 (20.9) 260 (26.4)
Marital status (% Married) 44.2 52.7
Children (% with biological children) 37.2 50.1
% with children under 18** 25.6 16.4
*p < 0.05
**p < 0.01
aN = 971 for GC Non-seekers (12 declined to answer)
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Table 2 Personal and family health information
Variable GC Seekers (N = 43) GC Non-seekers (N = 983)
Perceived general health*** (% reporting)
Poor 16.3 3.5
Fair 16.3 10.9
Good 27.9 29.9
Very good 32.6 40.4
Excellent 7.0 15.4
Mean number of conditions in personal medical historya 2.8 2.4
(sd, range) (2.4, 0–9) (2.1, 0–10)
Type of condition (% reporting)
GI conditionsb,c 40 29
Arthritisb,c 35 28
Asthmab 30 23
High cholesterolc 28 36
Mean number of conditions in blood relatives*a 7.7 6.61
(sd, range) (3.2, 0–13) (2.95, 0–14)
Type of condition (% reporting)
Cancerb,c 91 79
Arthritisb 74 64
High cholesterolb,c 70 68
Heart conditionsc 67 71
Mean # conditions of perceived increased risk*a 4.3 3.0
(sd, range) (3.7, 0–13) (2.6, 0–17)
Type of condition (% reporting)
Rheumatoid arthritisb 52 21
Osteoarthritisb 45 30
Celiac diseaseb 42 19
High cholesterolc 32 40
Heart diseasec 28 38
Skin cancerc 41 34
Previous genetic counseling (% reporting)*** 37.2 7.4
Previous genetic testing (% reporting)** 30.0 14.9
Type of testing
Diagnostic 9.3 3.9
Carrier 7.0 2.7
Predictive/Presymptomatic 4.7 2.7
Prenatal 4.7 0.9
Medication response 0 1.7
Ancestry* 2.3 6.8
Trait 0 0.8
Nutrigenomic 0 0.2
Otherd 7 2.7
Previous DTC-PGT 4.7 10.6
a Not all conditions listed, only the top 3 for each of the 2 cohorts
b Condition was one of top 3 cited by GC seekers
c Condition was one of top 3 cited by GC non-seekers
d Other types of genetic testing include paternity testing, research studies, and biobanks
*p < 0.05; **p < 0.01; ***p < 0.001
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Table 4 Frequency of different reactions to testing on 2-week survey
Variable GC Seekers (n = 40)† GC Non-seekers
(n = 875)†
% endorsing sometimes
or often (% endorsing often)
Distress
Worried about risk of disease 36.6 (7) 22.5 (3)
Disappointed about results 25 (3) 17.5 (3)
Upset about results 7.5 (0) 6.9 (2)
Uncertainty
Uncertain about what results mean about personal risk***a 60.0 (10) 27.2 (3)
Uncertain about what results mean for children 45.0 (8) 25.7 (4)
Unsure of what to do to prevent disease* 30.0 (8) 18.1 (2)
Concerned about how results will affect insurance status** 25.0 (8) 9.4 (1)
Had difficulty talking about results with others* 17.5 (5) 6.1 (1)
Positive reactions
Felt relieved about my results 72.5 (20) 65.7 (21)
Felt happy about results 70.7 (17) 77.0 (26)
Motivated to change lifestyle** 56.1 (27) 47.4 (11)
Other
Wanted to talk to others about my results 85.0 (34.9) 79.5 (21)
Felt surprised by my results 57.5 (13) 50.2 (7)
†Data was missing from 3 GC seekers and 108 GC non-seekers
a Significance levels refer to comparison between GC seekers andNon-seekers of proportion of respondents who had endorsed either the Bsometimes^ or
Boften^ option
*p < 0.05
**p < 0.01
***P < 0.001
Table 3 Motivations for pursuing personal genomic testing (PGT)
Factors in decision to pursue PGT GC Seekers (n = 40)† GC Non-seekers
(n = 875)†
n (%) rating as
‘very important’
Health-related Interest in risks for current or future children** 31 (77.5) 445 (50.9)
Interest in finding out my personal risk for specific diseases 31 (77.5) 542 (62)
Desire to create a better plan for the future*** 31 (77.5) 394 (45)
Desire to improve my health** 29 (72.5) 401 (45.8)
Interest in finding out about drug response*** 29 (72.5) 348 (39.8)
Other Curiosity about my genetic makeup 33 (82.5) 689 (78.8)
Desire to learn about my genetic makeup without going
through a physician
31 (72.5) 401 (45.8)
Personal interest in genetics in general 25 (62.5) 480 (54.9)
Desire to learn more about my genetics because I have
limited information about my family health history
18 (45) 305 (34.9)
The service seemed like it would be fun an entertaining 13 (32.5) 315 (36)
Other members of my family are using personal genomic services 6 (15) 84 (9.6)
Desire to learn more information about my genetics because I am adopted 2 (5) 42 (4.8)
†Data was missing from 3 GC seekers and 108 GC non-seekers
**p < 0.01
***P < 0.001
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Discussion
This is the first study to look beyond the proportion of DTC-
PGT customers who seek genetic counseling to identify how
consumers’ demographics, attitudes, and test results might
influence seeking a consultation. We found that 4% of con-
sumers in our study population sought genetic counseling for
their results. This is slightly higher than the 1% rate observed
byKaufman et al. (2012), but lower than the 14% rate reported
by Bloss et al. (2013), likely due to the fact that participants in
the latter study were provided with free access to GC services
through the DTC-PGT company. Given the moderate interest
in utilizing genetic counseling services reported by our partic-
ipants, the proportion of GC seekers may have been higher
had genetic counseling been more accessible. Lack of aware-
ness of, or experience with, accessing genetic counseling may
explain the low utilization rate observed here, given that the
strongest predictor of seeking GC for results was having had
genetic counseling prior to pursuing DTC-PGT. Over one-
third of GC seekers had prior experiences with genetic
counseling, compared to less than 10% of non-seekers. The
low rate of GC seeking could also be attributed to the fact that
many users were not pursuing testing for health reasons, but
rather for recreational reasons, such as general curiosity or for
ancestry information. Health-related motivators associated
with GC seeking in our study included learning about risks
to family members and carrier status.
Poorer self-reported health was an important predictor of
seeking genetic counseling, which is consistent with related
PGen study data indicating that some people seek DTC-PGT
to help explain a currently active medical condition, as op-
posed to identifying risks for potential future disease (Meisel
et al. 2015). GC seekers also tended to report a greater number
of conditions in their family medical history, which could
explain why they perceived being at increased risk for more
conditions than non-seekers. Participants frequently reported
personal and family histories of common, complex conditions
(such as arthritis, heart disease, and GI conditions) that are
seen in primary care or specialty settings and not typically
seen in genetics clinics. Given that generally there are no
specific genetic tests for these common, complex conditions
currently, some patients may have been seeking genetics
specialty care for a non-genetic condition, which could poten-
tially explain why there was no significant difference in visit
satisfaction levels for genetic counselors and primary care
physicians. Consumers may have been hoping for further test-
ing or medical recommendations from genetic counseling,
creating a potential mismatch between client expectations
and what medical providers can provide.
Predictors of seeking genetic counseling extend beyond par-
ticipants’ characteristics to their reactions to learning their re-
sults. After receiving results, GC seekers felt more motivated to
use them to improve their health than non-seekers but also
perceived a higher degree of uncertainty about their results.
Given the group’s high levels of numeracy, genetic knowledge,
and genetic self-efficacy, one might assume they would have
high comprehension of results. However, many DTC test re-
ports are complex and the personal health implications of test
results are often ambiguous, which may contribute to users’
uncertainty (Ostergren et al. 2015). Because the GC seekers
reported high motivation to improve their health but greater
uncertainty about results, they may have sought genetic
counseling to help clarify how their personal genetic informa-
tion can inform future health behaviors and medical care.
Consistent with previous studies, we found that consumers
were significantly more likely to share their results with their
PCP than a genetic counselor (Kaufman et al. 2012; Bloss
et al. 2013). Given that the conditions included in DTC-PGT
results are those typically seen in a primary care setting and
that PCPs are much more accessible than genetic counselors,
this result is not surprising and may, in fact, be entirely appro-
priate. Over half of GC seekers had also shared their results
with their PCP. Potential explanations for this finding include
needing a referral from a PCP to schedule a genetic counseling
appointment, lack of satisfaction with the initial PCP encoun-
ter, or lack of awareness of genetic counseling prior to
discussing the results with a PCP.
Consumers’ pre-test expectations may also be related to
perceptions of utility of DTC-PGT. GC seekers believed that
testing had significantly higher utility than non-seekers, yet
genetic counselors typically viewDTC-PGTas of lower utility
than customers do (Leighton et al. 2012). Consumers may
have incorrect perceptions about the utility of testing and put
more weight on the usefulness of results than the medical
professionals they are consulting. While consumers are more
likely to go to a PCP than a genetic counselor to discuss their
results, a survey of family and internal medicine providers
found that only 39% of PCPs were aware of DTC-PGT and
85% felt unprepared to answer patient questions about their
results (Powell et al. 2012).
Limitations and Future Directions
There are several limitations to this study. Participants are
early adopters of DTC-PGT and may not be representative
Table 5 Logistic regression model of variables predicting seeking
genetic counseling following DTC-PGT (N = 915)
Variable OR (95% CI) p-value
Previous GC 6.52 (3.1–13.8) 0.000
Health-related motivations for testing 4.27 (1.8–10.1) 0.001
Self-reported fair/poor health at baseline 3.07 (1.1–8.3) 0.026
Self-reported uncertainty about results 1.76 (1.1–2.7) 0.011
R-square = 0.204
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of the current population of DTC-PGT consumers.
Participants are also not representative of the general popula-
tion in terms of race, education level, and income. The small
sample size of GC seekers also limits the power of the study to
detect group differences in key study outcomes. Some survey
items may be prone to recall or other self-reporting biases and
some survey measures were developed by the research team
and/or not formally validated. The relatively short follow-up
time period may have meant missing some participants who
decided to seek GC services beyond the final 6-month survey.
We also lack detailed information on what specifically
prompted participants to seek GC, such as whether it was
the test results alone or a combination of the results and family
medical history. To address such study limitations, we need to
know more about the subjective experiences of DTC-PGT
consumers whose results prompt them to seek genetic
counseling. Qualitative research might be particularly useful
to explore this population’s motivations and counseling
experiences.
Conclusions
Genetic counselors may increasingly be asked to see patients
who are seeking counseling for their DTC-PGT results and
therefore an understanding of who seeks these services and
why is needed. Our results suggest this population may be
motivated to pursue testing to address current health problems
and to seek GC services to help resolve uncertainty surround-
ing their personal test results. These users may also be seeking
counseling for common complex conditions for which no
clinical genetic testing is currently available. The DTC-PGT
landscape has changed since this study was conducted, and
many SNPs with low associations with common disease risk
are no longer reported to the consumer. Nevertheless, genetic
counselors may be advised to address mismatches between
client expectations and what services can actually be offered,
to explore what clients had hoped testing would provide or
how they believed it could improve their health, and to address
potential misconceptions about the validity and utility of
testing.
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